Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways. Traditional oral options, including acetyl cholinesterase inhibitors and corticosteroids, remain foundational for early management, but the expanding presence of targeted categories is redefining clinical decision-making. Complement inhibitors—such as AstraZeneca’s eculizumab and ravulizumab, and UCB’s zilucoplan; and FcRn antagonists—such as Zai Lab’s efgartigimod alfa, and UCB’s rozanolixizumab— have broadened specialist choices. In parallel, BAFF/APRIL inhibitors such as RemeGen’s telitacicept are further diversifying the treatment landscape, influencing sequencing, duration of use, and siteofcare preferences. Despite these advances, a notable unmet need persists in ocular MG, where treatment options remain limited. Recent approvals of Inebilizumab (Hansoh Pharma’s Uplizna, March 2026) and nipocalimab (Johnson & Johnson’s Imaavy, May 2026) represent key progress in MG treatment. Meanwhile, late-phase programs, including Regeneron’s cemdisiran (monotherapy and FDC combination), AstraZeneca’s gefurulimab, Novartis’s iptacopan, and remibrutinib and others, signal continued diversification in targeted approaches and potential expansion of choices for generalized MG. This report provides a comprehensive evaluation of China’s MG therapy landscape, examining treatment patterns, unmet needs, and commercial outlook for current and emerging therapies, and evaluates how evolving pricing, coverage, and regulatory reforms may shape future launch and uptake dynamics.
QUESTIONS ANSWERED
- How large is China’s drug-treatable MG population, and how will drug-treatment rates change during the forecast period?
- What are the interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of MG?
- How will the MG therapy market evolve over the next 10 years?
- What are the drivers and constraints in the Chinese MG market, and how will the market evolve through 2035?
- How large is China’s drug-treatable MG population, and how will drug-treatment rates change during the forecast period?
PRODUCT DESCRIPTION·
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
Release date: July 2026
Geography: China (urban / rural)
Primary research: Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists in China
Epidemiology: Diagnosed prevalence of myasthenia gravis patients in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key myasthenia gravis therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments: Coverage of key current and late-phase emerging therapies
Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)
